Straits Times Index
3,283.09 -4.66 (-0.14%) Nikkei
37,963.45 +334.97 (+0.89%) Hang Seng
17,677.37 +392.83 (+2.27%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,539.70 +294.51 (+0.46%) CMC Crypto 200
1,389.18 +6.61 (+0.48%)
Invitae Corporation (0JDB.L)
| Previous close | 0.0003 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 225,013 |
| Market cap | 3,194 |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges. Amidst this financial turmoil, Invitae is actively exploring various strategic options,
- Zacks
Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock
Invitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- Zacks
What Makes Invitae (NVTA) a New Buy Stock
Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
